Peptides: which claims are backed by evidence in people?

Evidence as of September 2026.

Start with the result you want

Fewer heart attacks, less pain and a better laboratory result are different achievements. A claim about “peptides” tells you little until it names the treatment, the people studied and the outcome.

A peptide is a chain of amino acids, the building blocks also used to make proteins. That describes its structure, not its usefulness or safety. The sequence, preparation and way it enters the body matter. [1]

Where the evidence is strongest—and where it thins out

This is a map of evidence for particular uses, not a ranking of all peptides as a single class.

What a convincing benefit looks like

The SELECT trial provides a useful example. It enrolled 17,604 adults aged at least 45 who had cardiovascular disease and a body mass index of at least 27, but no diabetes. Over an average 39.8 months, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% of participants assigned semaglutide and 8.0% assigned placebo. [7]

That is an absolute difference of 1.5 percentage points—about 15 fewer people with an event per 1,000 treated over that period. It is a group result, not a prediction of one person's benefit. Treatment discontinuation because of adverse events was also more frequent: 16.6% versus 8.2%. Those figures describe stopping treatment, not the rate of all side effects. Novo Nordisk funded the study. [7]

In March 2024, the FDA approved Wegovy to reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, alongside diet and physical activity. Semaglutide mimics the action of GLP-1, including effects on appetite. The approval applies to a defined product and use, not every semaglutide preparation or a general promise of healthy aging. [3] [18]

Insulin is another established example. Humalog contains fast-acting insulin lispro and has been authorized in the EU since 1996 for diabetes requiring insulin. These medicines demonstrate what successful peptide development can achieve. They do not validate an unrelated experimental peptide. [2]

Three details that change the interpretation

1. A large set of notes can still leave the treatment effect unknown

A September 2026 BPC-157 preprint analyzed records from 1,039 people. Of the 354 with a recorded outcome, 279 were described as improved, 58 unchanged and 17 worse. Outcomes were missing for 685. About half received other agents, and there was no untreated comparison group. [9]

The reported improvements deserve investigation, but they are not a reliable success rate for BPC-157. Natural recovery and other treatments remain plausible explanations. Adverse effects were recorded as the reason for stopping in 24 of 129 documented discontinuations; that is not an overall adverse-event rate. The analysis used AI extraction with clinician spot-checks, and authors disclosed employment at nference. The report was a preprint and had not undergone peer review. [9]

2. A similar name can hide a different treatment

Full-length thymosin beta-4 has 43 amino acids. The TB-500 fragment assessed in FDA materials has seven, with a chemical modification called acetylation. They should not be treated as interchangeable. [10]

In the SEER-1 eye-drop trial, complete healing by day 29 occurred in 6 of 10 treated participants and 1 of 8 given placebo. The primary comparison missed the usual statistical threshold (p = 0.0656); a later day-43 result favored treatment. Recruitment stopped at 18 people rather than the planned 46. ReGenTree funded the trial, and some authors worked for the developer or its parent company. This is an uncertain eye-disease result, not evidence for injecting a fragment into an injured tendon. [11]

3. Measuring a natural signal is different from giving a treatment

In a 2021 study, researchers measured MOTS-c changes after exercise in 10 young men. The men did not receive MOTS-c. Separate experiments administered it to mice and found improvements in physical-function measures; the overall survival comparison was not statistically significant. Two authors disclosed consulting and shareholding relationships with CohBar. [12]

The registered MOTS-MET trial plans to test administered MOTS-c in adults with prediabetes and overweight or obesity. The cited trial entry describes a plan, not treatment results. Its value will be in what participants experience, not the fact that a study was registered. [13]

Availability, approval and safety are separate questions

The July 2026 FDA advisory meeting considered specified forms of seven substances for US section 503A compounding. Its recommendations were nonbinding. Nomination, an advisory recommendation, a final agency action and approval of a finished medicine are different events. A temporary enforcement policy is also distinct from the final ingredient list. [14] [15]

A US decision does not confer EU or Czech authorization. Under the EU centralized procedure, EMA assesses a medicine and the European Commission issues authorization; national routes also exist. Approval, reimbursement and local availability remain separate. Czech public-advertising rules add another constraint: SÚKL's October 2025 notice states that prescription medicines must not be advertised to the general public. [6] [17]

Quality matters even when the molecule has good evidence. FDA identifies semaglutide sodium and semaglutide acetate as different active ingredients from the one in approved products, without information establishing equivalent properties and action. A familiar name on a vial is not enough. [16]

What would change this picture?

Watch for completed, controlled human studies of the exact preparation, with meaningful benefits and harms reported for everyone enrolled. For MOTS-c, the next step is treatment results. For BPC-157, it is a comparison that can distinguish treatment from recovery and other care. For regulatory headlines, it is the dated final action and what it actually permits.

How Healthy Longevity Clinic experts evaluate the evidence

For Healthy Longevity Clinic, the value of peptide research lies in the health problem it can solve. A treatment that prevents cardiovascular events in a defined group and a compound that changes a laboratory marker answer different questions. The comparison in this article shows why the word “peptide” is too broad to guide a personal decision.

Our assessment starts with three links: does the study match the proposed product, do its participants resemble the person considering it, and does the result matter in daily life? SELECT provides a concrete example of a measurable benefit alongside measurable harms. The early BPC-157, TB-500 and MOTS-c evidence leaves important links unproven.

The practical takeaway is to bring a clear goal to a treatment discussion—such as recovering function or reducing a known health risk—and ask for the evidence connecting that goal to the exact preparation. That is how an interesting scientific idea becomes a useful clinical question.

Three questions to take to a consultation

1. What benefit should I notice in daily life, and how often did it occur compared with usual care or placebo?

2. Is this the same product, formulation and route used in the supporting study?

3. What are the known harms, the remaining uncertainties and the legal basis for this use here?

Common questions

Does “natural” mean safer?

No. A substance already present in the body can have different effects when supplied at a different dose or by a different route. Insulin's ability to lower blood sugar illustrates why dose and context matter. [2]

Can a biomarker show that a treatment works?

It can show a biological effect. Whether that translates into less illness or better function needs evidence linking the marker to that outcome.

If a clinic offers it, has its benefit been established?

Availability alone cannot answer that. Ask for the evidence and the precise regulatory basis, then assess them separately. [4] [5]